Lv4
708 积分 2021-06-13 加入
Evolution of TAVR as a Technology: Do Real-World Outcomes Still Support Expanded Use?
11小时前
已完结
From Passive to Proactive: A Call to Action on Valve Disease Screening
11小时前
已完结
Population Screening With Natriuretic Peptides Is Ready for Prime Time
11小时前
已完结
Four-Year Outcomes After Transcatheter or Contemporary Surgical Aortic Valve Replacement from the Evolut Low Risk Trial
11小时前
已完结
TAVI in 2015: who, where and how?
12天前
已完结
Long-Term Outcomes of Patients Requiring Pacemaker Implantation after Transcatheter Aortic Valve Replacement: The SwissTAVI Registry
3个月前
已完结
Cardiac Troponins and Cardiovascular Disease Risk Prediction
3个月前
已关闭
Cardiac Troponins and Cardiovascular Disease Risk Prediction
3个月前
已关闭
What Are the Implications of Choosing a TAVR-First Strategy in the Lifetime Management of Aortic Stenosis?: A Critical Review of TAVR-Explant- and Redo-TAVR
4个月前
已完结
Burden of Valvular Heart Diseases in a Racially and Ethnically Diverse Population: The Bronx‐Valve Registry
4个月前
已关闭
皖公网安备34019202002308
